100+ Free Cert Medical Oncology(SA) Phys Practice Questions

Explanation: In premenopausal women with node-negative HR+/HER2- breast cancer and an Oncotype DX Recurrence Score (RS) of 26-100, chemotherapy provides a substantial reduction in distant recurrence risk (TAILORx trial). For premenopausal women with RS 26-100, adjuvant chemotherapy followed by endocrine therapy incorporating ovarian function suppression (OFS) plus Tamoxifen or an Aromatase Inhibitor is standard. Tailored endocrine therapy with OFS yields superior outcomes in high-risk premenopausal patients (SOFT/TEXT trials).

Explanation: The CLEOPATRA trial established dual HER2-blockade with Pertuzumab, Trastuzumab, and Docetaxel as the gold-standard first-line systemic treatment for metastatic HER2-positive breast cancer. Dual targeting of HER2 subdomains II (pertuzumab) and IV (trastuzumab) produces synergistic inhibition of HER2 dimerization and downstream PI3K/AKT signaling, significantly improving overall survival compared to trastuzumab plus docetaxel alone.

Explanation: The DESTINY-Breast03 phase III trial demonstrated that Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate carrying a potent topoisomerase I inhibitor payload with a high drug-to-antibody ratio (8:1), provided statistically superior progression-free survival (PFS) and overall survival (OS) compared to T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Explanation: The KEYNOTE-522 trial established that adding Pembrolizumab to neoadjuvant chemotherapy (carboplatin + paclitaxel for 4 cycles, followed by doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide for 4 cycles), followed by adjuvant Pembrolizumab post-surgery, significantly improves pathological complete response (pCR) rate and event-free survival (EFS) in patients with stage II or III triple-negative breast cancer regardless of PD-L1 status.

Explanation: First-line systemic therapy for postmenopausal women with HR+/HER2- metastatic breast cancer without visceral crisis is a CDK4/6 inhibitor (Ribociclib, Abemaciclib, or Palbociclib) combined with an aromatase inhibitor (or Fulvestrant). Phase III landmark trials (MONALEESA-2, MONARCH-3, PALOMA-2) demonstrated significant improvements in median progression-free survival (doubling PFS to ~25-28 months) and overall survival (for Ribociclib and Abemaciclib).

Explanation: Olaparib is an oral Poly(ADP-ribose) Polymerase (PARP) inhibitor approved for germline BRCA1/2-mutated, HER2-negative metastatic breast cancer based on the OLYMPIAD trial. OLYMPIAD demonstrated a statistically significant improvement in median PFS (7.0 vs 4.2 months, HR 0.58) and response rate for Olaparib compared to physician's choice single-agent chemotherapy (capecitabine, eribulin, or vinorelbine). Talazoparib is similarly approved (EMBRACA trial).

Explanation: The monarchE phase III trial evaluated high-risk node-positive (>=4 positive nodes, or 1-3 positive nodes with Grade 3, tumor size >=5cm, or Ki-67 >=20%) HR+/HER2- early breast cancer. The addition of Abemaciclib (150 mg twice daily) for 2 years to standard adjuvant endocrine therapy significantly improved invasive disease-free survival (iDFS) and distant relapse-free survival (dRFS) with sustained benefit beyond completion of treatment.

Explanation: ASCO/CAP guidelines recognize ER-low positive breast cancers (ER 1-10%) as a distinct category. Broad genomic, transcriptomic, and clinical trial analyses demonstrate that the vast majority of ER-low positive tumors (>85%) have gene expression profiles and clinical outcomes identical to basal-like / triple-negative breast cancer (TNBC). They derive minimal benefit from endocrine therapy and should be managed with systemic chemotherapy strategies similar to TNBC.

Explanation: DESTINY-Breast04 established a new paradigm by demonstrating that Trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival and overall survival compared to physician's choice chemotherapy in patients with HER2-low (IHC 1+ or IHC 2+/FISH-negative) unresectable or metastatic breast cancer who had received one or two prior lines of chemotherapy.

Explanation: Combined analysis of the SOFT and TEXT phase III trials showed that premenopausal women with high-risk HR+ early breast cancer (especially those requiring adjuvant chemotherapy) achieved statistically significant improvements in disease-free survival and freedom from distant recurrence when treated with ovarian function suppression (OFS, e.g. Goserelin or Triptorelin) combined with an aromatase inhibitor (Exemestane) compared to Tamoxifen alone or OFS plus Tamoxifen.